Levosert (Levonorgestrel)

Levonorgestrel released from Levosert thickens cervical mucus, reduces sperm motility, suppresses the growth of the uterine lining, and may inhibit ovulation. These combined actions create an environment that prevents fertilisation and implantation.

Levosert contains a total of 52 mg of levonorgestrel, delivering about 20 µg per day. The exact dosing schedule and insertion timing are determined by the prescribing healthcare professional based on individual patient needs.

Levosert is intended for use in women who are not pregnant. If pregnancy occurs, the device should be removed promptly. Limited data are available for breastfeeding; clinicians usually assess risks and benefits before recommending use.

To order Levosert, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and necessary import documentation.

Levosert delivers a similar low‑dose levonorgestrel release as other IUDs such as Mirena, but it is approved for up to five years of use. Its design and release profile may differ slightly, offering clinicians an additional option based on patient preference and regulatory status.

Levosert should be stored at ambient temperature, below 25 °C, in its original sealed packaging. Protect the device from moisture, direct sunlight and extreme temperature fluctuations to maintain its integrity until insertion.

Levosert is inserted by a qualified healthcare professional into the uterine cavity using a specialized inserter. The procedure is performed in a clinical setting under sterile conditions, and patients are advised to schedule a follow‑up visit to confirm correct placement.

Serious risks include uterine perforation during insertion, expulsion of the device, pelvic inflammatory disease, and, in rare cases, ectopic pregnancy if conception occurs. Prompt medical attention is required if severe abdominal pain, abnormal bleeding, or signs of infection develop.

Levosert is contraindicated in women who are pregnant, have active pelvic infections, known or suspected uterine or cervical cancer, severe liver disease, unexplained vaginal bleeding, or a history of uterine perforation. A thorough medical evaluation is essential before placement.